Eptifibatide injection is an antiplatelet drug primarily used for thromboprophylaxis in acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). It is a colorless or almost colorless clear liquid, usually administered intravenously. Its effect is rapid and reversible, and it can significantly inhibit platelet function within 1 hour after intravenous administration. The effect can last for 2-4 hours, and platelet function gradually recovers after discontinuation of the drug. This characteristic gives it a unique advantage in clinical situations where rapid antiplatelet action is required and there may be a risk of bleeding.
Our Products Description
Eptifibatide COA
 |
||
| Certificate of Analysis | ||
| Compound name | Eptifibatide | |
| Grade | Pharmaceutical grade | |
| CAS No. | 188627-80-7 | |
| Quantity | 70g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090078 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.98% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage |
Store in a sealed, dark, and dry place below -20°C |
|
|
|
||
|
|
||
| Chemical Formula | C35H49N11O9S2 |
| Exact Mass | 831 |
| Molecular Weight | 832 |
| m/z | 831 (100.0%), 832 (37.9%), 833 (9.0%), 833 (7.0%), 832 (4.1%), 834 (3.4%), 833 (1.8%), 832 (1.6%), 833 (1.1%) |
| Elemental Analysis | 831 (100.0%), 832 (37.9%), 833 (9.0%), 833 (7.0%), 832 (4.1%), 834 (3.4%), 833 (1.8%), 832 (1.6%), 833 (1.1%) |
Eptifibatide injection, as a specific platelet glycoprotein IIb/IIIa receptor antagonist, plays an irreplaceable key role in the treatment of cardiovascular diseases by precisely inhibiting platelet aggregation. The following six aspects are included: treatment of acute coronary syndrome, assistance of percutaneous coronary intervention, prevention of thrombotic disease, improvement of vascular function, delay of atherosclerosis progress, and regulation of inflammatory reaction.
Treatment of acute coronary syndrome
Acute coronary syndrome (ACS) encompasses unstable angina and non ST segment elevation myocardial infarction, with its core pathological mechanism being the formation of thrombus in the coronary arteries, leading to myocardial ischemia. By specifically blocking the glycoprotein IIb/IIIa receptor on the surface of platelets, the binding of fibrinogen to this receptor is effectively inhibited. This binding process is a key pathway for platelet cross-linking and aggregation, and the intervention of eptipatide is like cutting off the key link of this pathway, thereby rapidly and effectively inhibiting platelet activation and aggregation, significantly reducing the risk of thrombosis, and reversing the blood deficiency caused by thrombosis.
Clinical studies have provided solid evidence for the effectiveness of treatment in acute coronary syndrome. In patients with unstable angina and non ST segment elevation myocardial infarction, the use of this substance in combination with aspirin and heparin treatment can significantly reduce the incidence of composite endpoint events such as death, myocardial infarction, or emergency revascularization within 30 days. This combination therapy strategy fully utilizes the synergistic effects of various drugs, with intervention from the platelet aggregation level by eptipatide, inhibition of platelet cyclooxygenase by aspirin to reduce the production of thromboxane A2, and anticoagulant effect by heparin. The combined action of the three provides patients with more comprehensive protection.
Its inhibitory effect has unique reversibility. After discontinuation, platelet function can gradually recover, which gives it a significant advantage in clinical situations where rapid antiplatelet action is required and there may be a risk of bleeding. For example, in patients with acute coronary syndrome, the peak blood drug concentration can be reached 5 minutes after intravenous injection, significantly inhibiting platelet function within 1 hour, and the effect lasts for 2-4 hours. This rapid onset and relatively short duration of action allows doctors to adjust treatment plans in a timely manner according to changes in the patient's condition, effectively controlling thrombosis while reducing the risk of long-term bleeding.
Source: 39Drug Tong, Minfukang, Baidu Baike
Assisted percutaneous coronary intervention therapy
Percutaneous coronary intervention (PCI) is an important treatment for coronary heart disease. However, catheter manipulation during the surgery may damage the vascular endothelium, activate platelets and coagulation systems, and lead to serious complications such as stent thrombosis. Plays multiple key roles during the perioperative period of PCI:
Preventing stent thrombosis formation
By continuously inhibiting platelet aggregation, the risk of stent surface thrombus attachment can be significantly reduced. Clinical studies have shown that continuous intravenous drip of etibacide after PCI can significantly reduce the incidence of stent thrombosis, especially for patients with complex diseases or high risk (such as diabetes, multi vessel disease). These patients have a higher risk of developing stent thrombosis due to poor vascular conditions or multiple underlying diseases, and the use of eptifibatide provides them with a more reliable safety guarantee.
Reduce the risk of late thrombotic events
Post PCI patients are at risk of late stage thrombus detachment leading to stroke and other distal embolism. By inhibiting platelet activation and reducing thrombus fragment shedding, the incidence of such events can be effectively reduced. For example, during PCI treatment, inserting a catheter through a vascular puncture into the heart's internal blood vessels may cause vascular damage. If the patient has a high risk of thrombus detachment, postoperative use of eptifibatide can reduce the risk of stroke caused by thrombus detachment and provide strong support for the patient's long-term prognosis.
As a short-term bridging therapy after thrombolysis and interventional procedures
For patients with acute ST segment elevation myocardial infarction, if timely intervention surgery is not possible or there are contraindications for thrombolysis, intravenous injection of eptifibatide can be given first to stabilize the condition, and intervention treatment can be carried out after conditions permit. In addition, for patients undergoing non extracorporeal circulation coronary artery bypass grafting, the combined use of eptipatide and sodium unfractionated heparin during the perioperative period can exert a synergistic anticoagulant effect, shorten the surgery and hemostasis time, and improve the success rate and safety of the surgery.
Source: 39Drug Tong, Minfukang, Baidu Baike
Prevention of thrombotic diseases
Thrombosis is a common pathological basis for various cardiovascular and cerebrovascular diseases, and eptifibatide injection plays an important role in the prevention of thrombotic diseases by inhibiting platelet aggregation
Prevent coronary artery stenosis or blockage
It can stabilize the atheromatous plaque, prevent its rupture from leading to thrombosis, and then prevent the occurrence of coronary stenosis or blockage. For patients with previous cardiovascular and cerebrovascular diseases, following the doctor's advice to take eptibatide for antiplatelet aggregation therapy can reduce the risk of recurrence of thrombotic diseases. For example, a patient who has suffered from myocardial infarction and continues to use it during rehabilitation can effectively reduce the possibility of coronary artery thrombosis re formation and protect heart function.
Prevent further blockage of blood vessels
After cardiac intervention surgery, if thrombosis occurs, it can be used under the guidance of a doctor to prevent further blockage of blood vessels. For example, for patients without contraindications such as bleeding, continuous intravenous infusion of eptifibatide after percutaneous coronary intervention can inhibit platelet aggregation on the stent surface, prevent vascular restenosis, and maintain vascular patency.
Reduce the risk of stroke
By inhibiting platelet aggregation and reducing distal embolism caused by thrombus shedding, the risk of stroke can be lowered. It is especially suitable for high-risk groups such as high heart rate, older age, previous anterior myocardial infarction, temporary cerebral ischemia or stroke, and diabetes history. These populations have a higher probability of developing stroke due to various risk factors, and their application provides them with an effective preventive measure.
Source: 39Drug Tong, Minfukang, Baidu Baike
Improvement of vascular function
Etriptide has multiple mechanisms of action in improving vascular function, providing comprehensive protection for cardiovascular health:
Expand coronary arteries
It can act on the smooth muscle of coronary arteries, causing them to relax, thereby increasing myocardial blood flow and improving the condition of insufficient blood supply to the heart. This effect helps alleviate angina symptoms and improve the quality of life for patients. For example, when a patient experiences myocardial ischemia due to coronary artery spasm, dilation can quickly alleviate the spasm, restore blood supply to the myocardium, and alleviate symptoms such as chest pain.
Promote endothelial cell repair
Endothelial cells play a crucial role in maintaining normal vascular function. It can stimulate damaged endothelial cells to release growth factors, accelerate endothelial cell migration and proliferation, help repair damaged vascular walls, and restore vascular function. For example, it can stimulate endothelial cells to produce nitric oxide (NO), which is an important endothelial relaxing factor that can diffuse to vascular smooth muscle cells, causing vasodilation, while also inhibiting platelet aggregation and adhesion, reducing the risk of thrombosis.
Regulating the proliferation and migration of vascular smooth muscle cells
The abnormal proliferation and migration of vascular smooth muscle cells are important causes of thickening of the vascular wall and narrowing of the lumen. By regulating the proliferation and migration of vascular smooth muscle cells, the function of the vascular wall is improved, and the smoothness of the vascular wall and smooth blood flow are maintained. For example, during the development of atherosclerosis, vascular smooth muscle cells will migrate from the middle membrane to the intima and proliferate, forming atherosclerotic plaques. Etibatide can inhibit this process and slow down the progression of atherosclerosis.
Source: 39Drug Tong, Baidu Baike
Delayed progression of atherosclerosis
Atherosclerosis is the pathological basis of coronary heart disease and stroke, and its progress is closely related to the level of low density lipoprotein cholesterol (LDL - C). The LDL - C level can be reduced by various ways, thereby slowing down or preventing the progression of atherosclerosis:
Inhibit LDL-C oxidation
Oxidative LDL - C is one of the key factors in the formation of atherosclerosis. Reduce the formation of foam cells by inhibiting the uptake of oxidized LDL - C. Foam cells are the main component of atherosclerotic plaque, and the reduction of its formation can effectively delay the development of atherosclerotic plaque.
Regulating lipid metabolism
Eptifibatide injection can affect the activity of lipid metabolism related enzymes and promote the synthesis of high-density lipoprotein cholesterol (HDL-C). HDL - C has the function of anti atherosclerosis. It can transport cholesterol in peripheral tissues to the liver for metabolism, thus reducing the level of cholesterol in the blood. Etriptide further improves cardiovascular health by regulating lipid metabolism disorders.
Source: 39Drug Tong
FAQ
Is eptifibatide an anticoagulant?
It is an anti-coagulant that selectively and reversibly blocks the platelet glycoprotein IIb/IIIa receptor.
What is eptifibatide used for?
Integrilin: Package Insert / Prescribing Information / MOAEptifibatide is a prescription platelet inhibitor (glycoprotein IIb/IIIa inhibitor) used in emergency cardiac care to prevent blood clots, heart attacks, or death. It is commonly administered intravenously to patients with acute coronary syndrome (ACS), including those with unstable angina, NSTEMI, or those undergoing percutaneous coronary intervention (PCI) with stenting.
Hot Tags: eptifibatide injection, China eptifibatide injection manufacturers, suppliers
